Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models.

ABSTRACT:

SUBMITTER: Nesic K 

PROVIDER: S-EPMC11903193 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature